← back to search

Guy Vernet

Institut Pasteur de Bangui · FR
Area of research
Epidemiology · Health, Toxicology and Mutagenesis
Research interest
Research interests include Respiratory viral infections research, Environmental Toxicology and Ecotoxicology, Viral gastroenteritis research and epidemiology, and Viral Infections and Immunology Research.
h-index
47
citations
7,486
works
274
NIH funding
primary concept
Medicine
email

Recent publications

Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic.
2023cited by 5position: contributordoi
High Fecal Carriage of Extended-Spectrum β-Lactamase Producing Enterobacteriaceae by Children Admitted to the Pediatric University Hospital Complex in Bangui, Central African Republic
Bacteria 2023cited by 2position: contributordoi
Tecovirimat for Monkeypox in Central African Republic under Expanded Access.
2022cited by 27position: contributordoi
Building an integrated serosurveillance platform to inform public health interventions: Insights from an experts’ meeting on serum biomarkers
PLoS neglected tropical diseases 2022cited by 24position: middledoi
Building an integrated serosurveillance platform to inform public health interventions: Insights from an experts' meeting on serum biomarkers.
2022cited by 16position: contributordoi
Seroprevalence of anti-SARS-CoV-2 antibodies before and after implementation of anti-COVID-19 vaccination among hospital staff in Bangui, Central African Republic
2022cited by 0position: contributordoi
Monkeypox treatment with tecovirimat in the Central African Republic under an Expanded Access Programme
2022cited by 0position: contributordoi
Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic
2021cited by 1position: contributordoi
Very High Relative Seroprevalence of Anti--SARS-CoV-2 Antibodies Among Communities in Bangui, Central African Republic
2021cited by 0position: contributordoi
Precision Public Health Through Serological Biomarkers: An Integrated Surveillance Platform to Inform Public Health Interventions
2021cited by 0position: contributordoi
Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward
Science Immunology 2020cited by 161position: middledoi
Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward.
2020cited by 115position: contributordoi
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
2020cited by 40position: contributordoi
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
2020cited by 32position: contributordoi
Surveillance for Antimicrobial Drug Resistance in Under-Resourced Countries
Emerging infectious diseases 2014cited by 105position: firstdoi
Pneumococcal colonisation density: a new marker for disease severity in HIV-infected adults with pneumonia
BMJ Open 2014cited by 47position: middledoi
Multicenter case–control study protocol of pneumonia etiology in children: Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL network)
BMC Infectious Diseases 2014cited by 35position: middledoi
High Incidence of Treatment-Induced And Vaccine-Escape Hepatitis B Virus Mutants Among Human Immunodeficiency Virus/Hepatitis B–Infected Patients
Hepatology 2013cited by 41position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 4 papers (2022–2023)Andrew S. Azman · University of Geneva4 papers (2020–2022)Matthew J. Ferrari · Pennsylvania State University2 papers (2020–2020)Henrik Salje · University of Cambridge2 papers (2022–2022)Isabel Rodriguez-Barraquer · Stanford University2 papers (2020–2022)Alexandre Manirakiza · Institut Pasteur de Bangui2 papers (2022–2023)Peter Horby · Johns Hopkins Hospital2 papers (2022–2022)Keith P. Klugman · Emory University2 papers (2014–2014)Benjamin F. Arnold · Centre de Recherche en Santé de Nouna2 papers (2020–2022)Seth Owusu‐Agyei · London School of Hygiene & Tropical Medicine2 papers (2020–2020)Kyla Hayford · Johns Hopkins University2 papers (2020–2022)Djibril Wade · University of Antwerp2 papers (2020–2022)Daniel T. Leung · University of Utah2 papers (2020–2022)Yap Boum · WWF Cameroon2 papers (2020–2020)Francisco J. Luquero · Gavi2 papers (2020–2020)Isabel Rodríguez-Barraquer · Global Solutions for Infectious Diseases2 papers (2020–2022)Fabien Zoulim · Inserm1 papers (2013–2013)Joseph T. Wu · Chongqing Medical University1 papers (2020–2020)Karine Lacombe · Centre de recherche en Epidémiologie et Santé des Populations1 papers (2013–2013)Shabir A. Madhi · Washington University in St. Louis1 papers (2014–2014)